

Special Issue

Challenges and Opportunities in Antibiotic Biosynthesis and Development

Message from the Guest Editor

Despite the available arsenal of drugs used to combat bacterial and fungal infections, these infectious diseases still constitute a leading cause of death. Several factors contribute to this scenario such as the spread of antimicrobials resistance, the rise in the number of immunocompromised and vulnerable patients, or the extended survival of patients in critical condition. Therefore, there is an urgent need for novel antimicrobials. In this context, natural products remain an invaluable source of lead compounds. This Special Issue welcomes both research and review papers in the most recent and innovative developments of antimicrobial biosynthesis. We hope the Special Issue can further encourage and promote the scientific contributions of the researchers in this field.

Guest Editor

Prof. Dr. Jesús F. Aparicio
Department of Molecular Biology, Universidad de León, 24071 Leon,
Spain

Deadline for manuscript submissions

closed (1 May 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/87749

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)